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Abstract 
Review on inv(3)(q21q26) RPN1/MECOM, with 
data on clinics, and the genes implicated. 
Identity 
Note 
The three chromosome anomalies are variants of 
each other, and they share identical features. 
Clinics and pathology 
Disease 
inv(3) and t(3;3) have been documented in de novo 
AML (in all FAB subtypes except M3), t-AML, s-
AML, myelodysplastic syndrome (MDS), chronic 
myelogenous leukaemia (CML), more often in 
accelerated phase or blast crisis, and in other 
myeloproliferative disorders. AML with 
inv(3)(q21q26) or t(3;3)(q21;q26) are part of the 
new WHO 2008 classification in the AML subgroup 
with recurrent genetic abnormalities. 
Phenotype/cell stem origin 
Hematopoietic stem cell with multilineage potential 
is implicated. 
Epidemiology 
inv(3)(q21q26) and t(3;3)(q21;q26) are the most 
common 3q abnormalities in AML (32%).  
The frequency of these rearrangements is estimated 
to range between 1.4% and 1.6% of AML in adults 
with no difference between sexes.  
These rearrangements are slightly more common in 
patients aged 60 years or younger, and extremely 
rare in pediatric AML. 
Clinics 
Patients may present a normal platelet count, 
however marked thrombocytosis may occur in 7% to 
22% of patients. 
Cytology 
Blasts express CD13, CD33, CD117, HLA-DR, 
CD56, CD34 and CD38; CD7 is aberrantly 
expressed in some cases, whereas the other lymphoid 
markers are uncommon; blasts may also express 
megakaryocytic markers such as CD41 or CD61. 
Blasts present morphologic and cytochemical 
features of any AML subtypes other than M3. 
Multilineage dysplasia is frequently associated with 
dysmegakaryopoiesis (characterized by small 
monolobate or bilobate megakaryocytes that can be 
increased in number).  
In peripheral blood, morphological abnormalities 
may be observed: hypogranular neutrophil, pseudo-
Pelger anomaly, macrothrombocytes, circulating 
micromegakaryocytes. 
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Prognosis 
Patients with inv(3)(q21q26) or t(3;3)(q21;26) 
present an aggressive course with short OS and poor 
response to conventional therapy (CR is estimated at 
31%). Studies describe an unfavourable 5-year 
survival rate (OS: 5.7%) with a median survival of 
10.3 months. OS is shorter, if additional monosomy 
7 is present. There is no difference in survival 
between inv(3) and t(3;3). 
Cytogenetics 
Note 
inv(3)(q21q26) are the most frequent abnormalities, 
ins(3;3)(q26;q21q26) are less frequent. 
Additional anomalies 
In AML, the most frequent additional anomaly is 
monosomy 7 (66% of cases), deletion 7q may occur 
in 3%, deletion 5q in 6%; complex karyotype is 
observed in 21% of cases, and monosomal karyotype 
in 68%. In CML, inv(3) or t(3;3) can be an additional 
anomaly to t(9;22)(q34;q11), but t(9;22) has also 
been found additional to inv(3). 
Genes involved and 
proteins 
MECOM 
Location 
3q26.2 
Note 
Alias EVI1. 
DNA/RNA 
EVI1 has 16 exons, and five alternative mRNA 5'-
ends: EVI1-1A, EVI1-1B, EVI1-1C, EVI1-1D and 
EVI1-3L. 
Protein 
EVI1 encodes a nuclear zinc finger protein that is a 
transcriptional regulator involved in cell 
proliferation, differentiation, and apopotosis. 
RPN1 
Location 
3q21 
DNA/RNA 
RPN1 has 10 exons. 
Protein 
RPN1 encodes a transmembrane glycoprotein, 
localized in the rough endoplasmic reticulum. 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
inv(3)(q21q26) or t(3;3)(q21q26) lead to a 
juxtaposition of the region surrounding the RPN1 
gene in 3q21 with the EVI1 gene in 3q26. 
Breakpoints occur about 900 kb located 5' and 3' to 
the EVI1 gene with the t(3;3) and the inv(3) 
respectively. Breakpoints in the RPN1 gene area 
span over 235 kb and are either located 3' or 
centromeric to the RPN1 gene.  
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Boxes represent genes. Breakpoints in 3q26.2 locus are distributed on each side of EVI gene: 5' in t(3;3) and 3' in inv(3). GATA2 
= GATA Binding Protein 2; G2DHE = GATA2 distal hematopoietic enhancer. Diagram is not to scale. Courtesy Thomas Smol. 
Recently, studies have described a role for G2DHE, 
GATA2 distal hematopoietic enhancer, that is 
located 160 kb 3' to the RPN1 gene on 3q21. In 
3q21q26 rearrangements, G2DHE is juxtaposed to 
EVI1 and is thought to induce EVI1 gene 
transcription instead of GATA2 and thus promote 
leukemogenesis. 
To be noted 
Note 
AML with inv(3) or t(3;3) are associated with NRAS 
mutations (28%), FLT3-ITD mutations (less than 
20%), and rare NPM1 mutations. 
EVI1 overexpression has been described without 
3q21q26 rearrangement and conversely, there are 
extremely rare cases of 3q21q26 rearrangement 
without EVI1 overexpression.  
Recently, Groschel et al. have observed that 98% of 
myeloid malignancies with inv(3) and t(3;3) present 
mutations in gene activating RAS/RTK signalling 
pathways. 
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